Titlebook: Anticancer Drug Development Guide; Preclinical Screenin Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 cancer.c

鬼魂

Fertile Seed and Rich Soilthe tumor would behave in the rodent in a similar manner as it did in the patient. Such models would be useful for the individual patient treatment design and for evaluation of new antineoplastic agents and procedures.

逃避責(zé)任

Book 1997itor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.

constitutional

2196-9906 arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. The

刺穿

NIB

uveitis

結(jié)構(gòu)

Murine L1210 and P388 Leukemiastly reduced level. This chapter reviews their past and present roles in the evaluation of anticancer drugs. Data for the sensitivity of these two leukemias and the drug-resistant P388 sublines to clinically useful drugs are reported.

PALL

Phase I Trial Design and Methodologying the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical Phase I study will be reviewed in this chapter with an emphasis on potential innovative approaches to streamline and improve the current design and practice of such trials.

Bridle

Phase II Clinical Trials in Oncologyatment protocol. By specifying in this document the target group of patients, the treatment conditions, and the desired criteria of success or failure, potential sources of bias are minimized. The treatment evaluation is thus based on objective results rather than deductive reasoning (.).

果核

Grenzwerte und stetige Funktionen,I for further evaluation in other tumor models or alternative screens. Most of the available clinical anticancer agents are active in the P388 system; however, most were discovered prior to 1975 or by observations initially in test systems other than the NCI-operated P388 primary screen.